Company profile for Kiora Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Kiora Pharmaceuticals, Inc. (Kiora) is an ophthalmic specialty pharmaceutical company that develops therapies for the treatment of different types of eye diseases. Publically traded on the NASDAQ under KPRX, our mission is to help patients improve their ocular health and restore vision.Kiora’s pipeline has recently expanded from one to three clinical stage candidates (with multiple possible indications). Stay tuned as the ne...
Kiora Pharmaceuticals, Inc. (Kiora) is an ophthalmic specialty pharmaceutical company that develops therapies for the treatment of different types of eye diseases. Publically traded on the NASDAQ under KPRX, our mission is to help patients improve their ocular health and restore vision.Kiora’s pipeline has recently expanded from one to three clinical stage candidates (with multiple possible indications). Stay tuned as the new management team advances these assets with key clinical milestones in the upcoming 12 to 18 months.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1371 East 2100 South Suite 200 Salt Lake City, UT 84105
Telephone
Telephone
1-781-788-8869
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/kiora-pharmaceuticals-joins-rare-x-vision-consortium-promoting-collaboration-and-development-of-new-treatments-for-rare-ocular-disorders-302599561.html

PR NEWSWIRE
30 Oct 2025
Cash-strapped eye disease biotech halves portfolio
Cash-strapped eye disease biotech halves portfolio

08 Aug 2023

// Gabrielle Masson FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/cash-strapped-kiora-sharpens-focus-rare-retinal-diseases-looks-partner-other-assets

Gabrielle Masson FIERCE BIOTECH
08 Aug 2023

https://www.prnewswire.com/news-releases/groundbreaking-clinical-trial-underway-to-improve-vision-in-individuals-with-advanced-retinitis-pigmentosa-rp-301746841.html

PR NEWSWIRE
14 Feb 2023

https://www.clinicaltrialsarena.com/news/kiora-pced-therapy-trial/

CLINICAL TRIALS ARENA
05 Jan 2023

https://ir.kiorapharma.com/news-events/press-releases/detail/165/kiora-pharmaceuticals-announces-publication-of-phase-1

PRESS RELEASE
17 Oct 2022

https://ir.kiorapharma.com/news-events/press-releases/detail/164/kiora-pharmaceuticals-regains-compliance-with-nasdaq

PRESS RELEASE
13 Oct 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty